Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: A clinical study on maximum tolerable dose and treatment efficacy

Journal of Cancer Research and Clinical Oncology

Volumn 132, Issue 11, 2006, Pages 745-755

  Vogl, Thomas J ^a   Schwarz, Wolfram ^a   Eichler, Katrin ^a   Hochmuth, Kathrin ^a   Hammerstingl, Renate ^a   Jacob, Ursula ^b   Scheller, Albert ^b   Zangos, Stephan ^a   Heller, Matthias ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Oncological Clinic Heilbrunn Leonardis Clinic   (Germany)

Author keywords

Cholangiocarcinomas; Gemcitabine; Intraarterial chemotherapy; Liver metastases

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GEMCITABINE; STARCH MICROSPHERE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BLOOD TOXICITY; BODY WEIGHT; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; KIDNEY DISEASE; LABORATORY TEST; LEUKOPENIA; LIVER METASTASIS; LUNG DISEASE; LUNG EDEMA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROLOGIC DISEASE; PANCREAS CANCER; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; WEIGHT GAIN;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33748363484     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-006-0138-0     Document Type: Article

References (56)

1. Al-Bassam SH, Munk PL, Sallomi DF et al (1999) Chemoembolization of hepatic tumours. Australas Radiol 43:165-174
2. Asthana S, Jones D, Lodge JP (2006) Surgical management of recurrent liver tumors involving hepatic venous outflow. J Am Coll Surg 202(4):711-713
3. Barton-Burke M (1999) Gemcitabine: a pharmacologic and clinical overview. Cancer Nurs 22(2):176-183
4. Bengmark S, Ekberg H, Tranberg KG (1988) Metastatic tumors of the liver. In: Blumgart LH (eds) Surgery of the liver and biliary tract, vol 2. Churchill Livingstone, Edinburgh, London, Melbourne, New York, pp 1179-1189
5. Bosch FX, Ribes J (2000) Epidemiology of liver cancer in Europe. Can J Gastroenterol 14:621-630
6. Bosch FX, Ribes J, Borras J (1999) Epidemiology of primary liver cancer. Semin Liver Dis 19:271-285
7. Bourgeois H, Billiart I, Chabrun V et al (2004) Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma. Am J Clin Oncol 27:89-94
8. Brasiuniene B, Juozaityte E, Brasiunas V, Inciura A (2003) The update on pancreatic cancer chemotherapy. Medicina (Kaunas) 39:1016-1025
9. Burris H, Storniolo AM (1997) Assessing the clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 33(suppl 1):191-201
10. Cenusa A (2005) Hepatocellular carcinoma therapeutic action: hepatic resection and liver transplantation. Rev Med Chir Soc Med Nat Iasi 109(4):709-712
11. Falconi M, Bassi C, Bonora A et al (1999) Role of chemoembolization in synchronous liver metastases from pancreatic endocrine tumors. Dig Surg 16:32-38
12. Geffen DB, Man S (2002) New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J 4(12):1124-1131
13. Gitlitz BJ, Baker C, Chapman Y, Allen HJ et al (2003) A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98:1863-1869
14. Gores GJ (2000) Early detection and treatment of cholangiocarcinoma. Liver Transpl 6:S30-S34
15. Gronbaek H, Levertumorgruppen AS (2006) Hepatocellular carcinoma and other liver tumors. The Danish Society of Hepatology (DASL) Ugeskr Laeger 168(12):1219
16. Guarneri V, Conte PF (2004) The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging. Jun; 31(Suppl 1):S149-S161 [Epub 2004 Apr 24 review]
17. Hanack U, Lorf T, Binder L et al (1999) Surgical treatment of cholangiocellular carcinoma. Swiss Surg 5:111-115
18. Huang JL, Biehl TR, Lee FT et al (2004) Outcomes after resection of cholangiocellular carcinoma. Am J Surg 187:612-617
19. Hui YF, Reitz J (1997) Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 54:162-170; quiz 197-198
20. Jones SM, Roh MS (2001) Results of surgical resection for hepatocellular carcinoma. Cancer Treat Res 109:59-75
21. Kemeny N, Huang Y, Cohen AM et al (1999) Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341:2034-2048
22. Klapdor R, Seutter E, Lang-Polckow EM et al (1999) Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers. Anticancer Res 19:2459-2469
23. Kubicka S, Rudolph KL, Tietze MK et al (2001) Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 48:783-789
24. Lamesch P, Weimann A, Hauss J, Pichlmayr R (1997) Surgical treatment of intrahepatic cholangiocarcinoma. Chirurgie 122:88-91
25. Llovel JM (2005) Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40(3):225-235
26. Lorf T, Hanack U, Schworer H et al (2000) Surgical treatment of cholangiocellular carcinoma and proximal bile duct tumors. Zentralbl Chir 125:637-641
27. Malhi H, Gores GJ (2006) Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Ther 1 23(9):1287-1296
28. Margarit C, Escartin A, Bellmunt J, Allende E, Bilbao I (2006) Peripheral cholangiocarcinoma: results of surgical treatment. Gastroenterol Hepatol 29(4):215-223
29. Martin R, Jarnagin W (2003) Intrahepatic cholangiocarcinoma. Current management. Minerva Chir 58:469-478
30. Nakajima Y, Ko S, Kanamura T, Nagao M, Kanehiro H, Hisanaga M, Aomatsu Y, Ikeda N, Nakano H (2001) Repeat liver resection for hepatocellular carcinoma. J Am Coll Surg 192(3):339-344
31. Pawlik TM, Scoggins CR, Thomas MB, Vauthey JN (2004) Advances in the surgical management of liver malignancies. Cancer J 10(2):74-87
32. Price P (2001) Cholangiocarcinoma and the role of radiation and chemotherapy. Hepatogastroenterology 48:51-52
33. Raguse JD, Gath HJ, Bier J, Riess H, Oettle H (2005) Gemcitabine in the treatment of advanced head and neck cancer. Clin Oncol (R Coll Radiol) 17(6):425-429
34. Reid JM, Qu W, Safgren SL, Ames MM et al (2004) Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol 22:2445-2451
35. Ringe B, Weimann A, Lamesch P et al (1994) Liver transplantation as an option in patients with cholangiocellular and bile duct carcinoma. Cancer Treat Res 69:259-275
36. Sakaguchi H, Uchida H, Tanaka T et al (2001) Transcatheter arterial embolization/chemoembolization. Nippon Rinsho 59(Suppl 6):521-527
37. Sandler AB, Kindler HL, Einhorn LH et al (2000) Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol 11:1161-1164
38. Sasson AR, Sigurdson ER (2002) Surgical treatment of liver metastases. Semin Oncol 29(2):107-118
39. Spagnuolo P, Roversi R, Rossi G et al (1999) Phase II study of gemcitabine for treatment of inoperable pancreatic and cholangiocarcinoma. Proc Am Soc Clin Oncol 18:1170
40. Srivatanakul P, Sriplung H, Deerasamee S (2004) Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev 5:118-125
41. Starkhammer H, Hakansson L, Morales O, Svedberg J (1987) Intraarterial Mytomycin C treatment of unresectable liver tumors. Preliminary results on the effect of degradable starch microspheres. Acta Oncol 26:295-300
42. Stuart K (2003) Chemoembolization in the management of liver tumors. Oncologist 8(5):425-437
43. Tannapfel A, Wittekind C (2004) Gallbladder and bile duct carcinoma. Biology and pathology. Internist (Berl) 45(1):33-41
44. Tarazov PG (2001) Preoperative arterial chemoembolization in malignant tumors of the liver. Vestn Khir Im I Grek 160:119-123
45. Tarcoveanu E, Lupascu C, Georgescu S, Zugun F, Crumpei F, Epure O, Nicorici C, Canschi G, Ferariu D (2005) Liver resection for hepatocellular carcinoma in cirrhotic patients. Rev Med Chir Soc Med Nat Iasi 109(4):770-780
46. Toschi L, Finocchiaro G, Bartolini S, Gioia V, Capuzzo F (2005) Role of gemcitabine in cancer therapy. Future Oncol 1(1):7-17
47. Tsavaris N, Kosmas C, Gouveris P et al (2004) Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 22:193-198
48. Uenishi T, Hirohashi K, Shuto T et al (2000) Surgery for mixed hepatocellular and cholangiocellular carcinoma. Hepatogastroenterology 47:832-834
49. Verderame F, Mandina P, Abruzzo F et al (2000) Biliary tract cancer: our experience with gemcitabine treatment. Anticancer Drugs 11:707-708
50. Vogl TJ, Heller M, Zangos S, Schwarz W et al (2003) Transarterial chemoperfusion of inoperable pancreas carcinoma and local recurrence. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 175:695-704
51. Weissmann A, Ludwig H (1999) Intraarterial gemcitabine for treatment of inoperable pancreatic and cholangiocarcinoma. Proc Am Soc Clin Oncol 18:1170
52. Xiao EH, Hu GD, Li JQ, Huang JF (2005) Transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 27(8):478-482
53. Yalcin S (2004) Diagnosis and management of cholangiocarcinomas: a comprehensive review. Hepatogastroenterology 51:43-50
54. Yu L, Sloane DA, Guo C, Howell CD (2006) Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol 4(3):355-60
55. Yu MC, Yuan JM, Govindarajan S, Ross RK (2000) Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 14:703-709
56. Zaloudik J, Kocak I, Pacovsky Z, Karasek P, Fait V, Bartonkova H, Nekulova M (1997) Regional chemotherapy of liver tumors. Vnitr Lek 43(3):171-172